ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2387

Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study

Nazanin Naderi1, Aladdin Mohammad2, Karin Wadström3, Ulf Bergström3 and Carl Turesson3, 1Lund University, Kristiandstad, Sweden, 2Lund University, Lund, Sweden, 3Lund University, Malmö, Sweden

Meeting: ACR Convergence 2023

Keywords: Comorbidity, giant cell arteritis, Infection, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Manifestations of giant cell arteritis (GCA) include large vessel involvement (LVI) of the aorta and its branches. Aortic aneuryms are more common compared to the general population. GCA is complicated by an increased risk of infections, likely due to treatment and/or the systemic nature of the disease. There is limited information on the impact of the disease phenotype on the risk of infection among patients with GCA. No previous study has investigated LVI in GCA as a risk factor for severe infections. Such investigations need to take into account demographics and comorbidities. The objective of this study was to assess the influence of age, sex, LVI and pre-existing comorbidities on the risk of severe infection in GCA.

Methods: Patients with biopsy-proven GCA, diagnosed between 2002 and 2010, were identified from a regional pathology register, and followed through the end of study December 2011.
Data on infections requiring hospitalization were obtained from linkage to the regional healthcare registry. Twenty categories of infections were identified based on ICD-10 codes.
Five categories of pre-existing comorbidities were based on diagnoses registered within four years before the date of GCA diagnosis, and the Charlson comorbidity index (CCI) was calculated. Information on LVI was obtained through structured review of all relevant radiological and clinic-physiological studies. LVI was defined as presence of aneurysm, ectasia, or stenosis of the aorta and/or its main branches or positive 18fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography or other nuclear imaging methods indicating vasculitis. Patients with LVI findings after or ≤1 year before the GCA diagnosis were classified as having the LVI phenotype. Cox regression analysis was used to identify possible predictors of severe infections among patients with GCA. Patients were followed from time of GCA diagnosis and censored at death or migration from the region. Covariates were excluded from multivariate models based on co-linearity.

Results: Among 516 patients with biopsy-proven GCA (Table 1), 19.4% had confirmed LVI, and 12% had aortic involvement (aneurysm, ectasia, dissection or signs of vasculitis on nuclear imaging) with or without concomitant distributary artery affection. There were 118 patients with ≥1 severe infection during the study period.

Higher age at diagnosis and several pre-existing comorbidities, i.e. coronary artery disease, heart failure, diabetes, chronic obstructive pulmonary disease and renal failure were significant predictors for severe infections (Table 2). LVI overall and aortic involvement were associated with significantly increased risk of severe infections in age-adjusted analyses (Table 2). In the multivariate analysis, aortic involvement was predictive of severe infections (Hazard ratio 1.75; 95% confidence interval 1.04-2.94, adjusted for age and comorbidities) (Table 3).

Conclusion: In patients with GCA, age and specific pre-existing medical conditions are predictors of severe infections. LVI, in particular of the aorta, may also be associated with a higher risk for severe infection.

Supporting image 1

Table 1

Supporting image 2

Table 2

Supporting image 3

Table 3


Disclosures: N. Naderi: None; A. Mohammad: None; K. Wadström: None; U. Bergström: None; C. Turesson: AbbVie/Abbott, 6, Bristol-Myers Squibb(BMS), 5, Pfizer, 6.

To cite this abstract in AMA style:

Naderi N, Mohammad A, Wadström K, Bergström U, Turesson C. Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/large-vessel-involvement-and-the-risk-of-severe-infections-in-patients-with-giant-cell-arteritis-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/large-vessel-involvement-and-the-risk-of-severe-infections-in-patients-with-giant-cell-arteritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology